伊匹木单抗联合纳武利尤单抗治疗需使用糖皮质激素的症状性黑色素瘤脑转移患者
这项回顾性队列研究纳入2016至2021年在皇家马斯登医院伦敦院区接受伊匹木单抗联合纳武利尤单抗、同时使用糖皮质激素的29例症状性黑色素瘤脑转移患者,中位总生存期为5.45个月,颅内客观缓解率为28%(8/29),缓解者中位总生存期达56.4个月。
要点
- 症状性黑色素瘤脑转移且需糖皮质激素者从联合免疫治疗中获益有限,中位总生存期5.45个月。
- 颅内客观缓解率为28%(8/29),缓解持续时间7.85个月。
- 缓解者中位总生存期达56.4个月,提示部分患者可能获得长期获益。
核心结论
- 症状性黑色素瘤脑转移患者从联合免疫治疗中仅获得有限获益。
- 但治疗缓解者有可能获得长期获益,在缺乏其他更有效治疗选择的情况下,支持该组患者使用伊匹木单抗联合纳武利尤单抗。
研究设计与样本
- 回顾性队列研究,纳入2016至2021年在皇家马斯登医院伦敦院区接受PD-1导向抗体治疗的皮肤黑色素瘤伴症状性脑转移且同时使用糖皮质激素的患者。
- 共29例符合条件的患者接受伊匹木单抗联合纳武利尤单抗治疗,中位年龄54岁(四分位距44,66)。
- 主要结局为总生存期,次要结局为颅内客观缓解率和缓解持续时间,采用Kaplan-Meier法描述生存。
主要发现
- 中位总生存期为5.45个月(95%CI 2.89,29.40),3年生存率为21%(95%CI 9%,47%)。
- 颅内客观缓解率为28%(8/29),缓解持续时间为7.85个月(95%CI 7.85,不可估计)。
- 缓解者的中位总生存期为56.4个月(95%CI 46.03,不可估计)。
- 乳酸脱氢酶升高和东部肿瘤协作组体能状态评分>2与较差结局相关,中位总生存期分别为29.4个月对3.12个月和6.44个月对5.13个月。
- 糖皮质激素剂量、病灶数目或治疗线数与结局未见此类关联。
临床怎么用
- 作者认为,在缺乏其他更有效治疗选择的情况下,症状性黑色素瘤脑转移且需糖皮质激素的患者使用伊匹木单抗联合纳武利尤单抗具有合理性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY AIM: To investigate the efficacy of PD-1-directed antibody-based therapy in patients with symptomatic melanoma brain metastases (MBM) and concurrent treatment with corticosteroids. METHODS: This retrospective cohort study included patients with cutaneous melanoma with symptomatic MBM and concurrent treatment with corticosteroids who received PD-1-directed antibody-based treatment at the Royal Marsden Hospital London between 2016 and 2021. The primary outcome was overall survival (OS), secondary outcomes were intracranial response rate (ORR) and duration of response (DOR). We used the Kaplan-Meier method to describe survival. RESULTS: Between 2016 and 2021, 256 patients presented with metastatic melanoma, of whom 29 were eligible with symptomatic MBM requiring corticosteroids and receiving ipilimumab plus nivolumab. Median age was 54 (interquartile range 44, 66). Median OS was 5.45months (95% confidence interval (CI) 2.89, 29.40), with 21% of patients (95% CI 9%, 47%) alive after 3years. ORR was 28% (8/29) and DOR was 7.85months (95% CI 7.85, not estimably [NE]). Responding patients had a median OS of 56.4months (95% CI 46.03, NE). Elevated lactate dehydrogenase and Eastern Cooperative Oncology Group PS> 2 were associated with poorer outcomes (median OS 29.4 versus 3.12months and 6.44 versus 5.13months), no such association was observed for corticosteroid dose, number of lesions, or line of treatment. CONCLUSION: Patients with symptomatic MBM derive only modest benefit from combination immunotherapy treatment. Nevertheless, those with disease response have the potential to derive long-term benefit, justifying ipilimumab plus nivolumab in this group in the absence of other more effective treatment options.
引用
- Manacorda S, Carmena MT, Malone C, et al. Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids. Eur J Cancer. 2023. PMID: 37229837. doi:10.1016/j.ejca.2023.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。